Skip to main content

Remote Job Finders (RJF)

Galapagos Exits Cell Therapy, Cuts 365 Employees

Galapagos at the start of the year had planned to split into two businesses, with one resulting entity focused on cell therapies. The biotech nixed these plans a few months later, instead choosing to put up for sale multiple cell therapy assets.

Summit Eyes 2025 FDA Application for Ivonescimab Despite Overall Survival Miss

In May, Summit released early data from the Phase III HARMONi study showing that while the PD-1/VEGF inhibitor resulted in significant progression-free survival improvements, it fell short of the overall survival bar.
Scroll to top